CRP and colorectal cancer: The instrument of TNF-inhibition was associated with a significantly lower risk of colorectal cancer, and the results showed an absolute risk reduction of 2.1% (the IVW analysis, 95%CI 0.4%–3.8%, p = 0.012) per 1 mg/L reduction in CRP.